CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The firm is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Follow-Up Questions
Who is the CEO of CASI Pharmaceuticals Inc?
Dr. Wei-Wu He is the Chairman of the Board of CASI Pharmaceuticals Inc, joining the firm since 2012.
What is the price performance of CASI stock?
The current price of CASI is $1.71, it has decreased 1.72% in the last trading day.
What are the primary business themes or industries for CASI Pharmaceuticals Inc?
CASI Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is CASI Pharmaceuticals Inc market cap?
CASI Pharmaceuticals Inc's current market cap is $26.4M
Is CASI Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for CASI Pharmaceuticals Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
